WO2019184995A1 - Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 - Google Patents

Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 Download PDF

Info

Publication number
WO2019184995A1
WO2019184995A1 PCT/CN2019/080213 CN2019080213W WO2019184995A1 WO 2019184995 A1 WO2019184995 A1 WO 2019184995A1 CN 2019080213 W CN2019080213 W CN 2019080213W WO 2019184995 A1 WO2019184995 A1 WO 2019184995A1
Authority
WO
WIPO (PCT)
Prior art keywords
filtrate
purified
unit
purification
recombinant
Prior art date
Application number
PCT/CN2019/080213
Other languages
English (en)
French (fr)
Inventor
洪谊
闫听
应降果
张豪杰
张丽
王飞
赵荻骏
张露亿
Original Assignee
上海赛比曼生物科技有限公司
无锡赛比曼生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海赛比曼生物科技有限公司, 无锡赛比曼生物科技有限公司 filed Critical 上海赛比曼生物科技有限公司
Priority to KR1020207030556A priority Critical patent/KR20200136448A/ko
Priority to SG11202009824WA priority patent/SG11202009824WA/en
Priority to JP2020552824A priority patent/JP2021518757A/ja
Priority to EP19778302.0A priority patent/EP3778905A4/en
Priority to US17/042,125 priority patent/US20210009966A1/en
Priority to AU2019241300A priority patent/AU2019241300A1/en
Publication of WO2019184995A1 publication Critical patent/WO2019184995A1/zh
Priority to US17/034,168 priority patent/US20210147826A1/en
Priority to JP2023210248A priority patent/JP2024041758A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Definitions

  • the present invention relates to the field of biotechnology, and in particular to a method for preparing a purified preparation of a recombinant lentiviral vector on a GMP scale.
  • Gene therapy refers to the introduction of an exogenous therapeutic gene into a target cell to correct or compensate for a disease caused by a gene defect or abnormality, or a product of expression of a foreign gene acting on a disease target for therapeutic purposes.
  • the foreign gene can be transduced or delivered by a viral vector or a non-viral vector.
  • the commonly used non-viral vectors are liposomes, dendrimers, non-natural cationic polymers, natural polysaccharides and the like. Non-viral gene delivery vectors are safer and more stable, but their transfection efficiency is usually lower.
  • the viral vector is a foreign gene packaged into the outer shell of a natural virus, and the foreign gene is introduced into the cell by utilizing the infectivity of the virus to the host cell.
  • Common viral vectors include retrovirus (rRV), recombinant lentivirus (rLV), recombinant adenovirus (rAd), and recombinant adeno-associated virus (rAAV).
  • the transduction efficiency of viral vectors is much higher than that of non-viral vectors, and is particularly suitable for infecting target cells, such as lymphocytes, which are difficult to infect.
  • the recombinant chronic disease vector is a gene therapy vector developed on the basis of HIV-1 (human immunodeficiency type I virus). It distinguishes between a general retroviral vector, which is capable of infecting both dividing cells and non-dividing cells. Recombinant chronic disease vectors have become the preferred transgenic vectors for CART cells and gene therapy because of their high biological titer and low immunogenicity in vitro and in vivo.
  • the current recombinant lentiviral vector is a genetically engineered method that leaves only the packaging signal and the target gene transcript in the lentiviral genome, and disperses the structural genes such as reverse transcriptase, envelope protein VSVG, and gag-pol in 2 On ⁇ 3 vectors, the disease-causing gene was deleted at the same time.
  • the mature lentiviral particles are obtained by co-transfecting 293T cells into a cell and then secreting them into the culture supernatant by 293T cells, which can be obtained by ultracentrifugation or chromatographic purification.
  • the method used by conventional laboratories to obtain lentiviruses is ultracentrifugation. Although this method is simple but cannot be industrially amplified, the prepared lentiviral vector may have high endotoxin, BSA, HCP or nucleic acid residues, and cannot be directly used. In the human body.
  • the existing chromatographic purification methods also have the disadvantages of cumbersome steps, low yield and high purity, and are difficult to meet the requirements of industrial large-scale production and GMP-level production.
  • Another object of the present invention is to provide a recombinant lentivirus purified by the method, and a purified preparation containing the recombinant lentivirus and use thereof.
  • a method of scale-up purification of a recombinant viral vector preparation comprising the steps of:
  • the liquid is subjected to microfiltration treatment to obtain a microfiltration-treated filtrate, wherein the filtrate contains the recombinant viral vector, the volume of the filtrate is Vb;
  • the chromatography is selected from the group consisting of anion chromatography, size exclusion chromatography, multi-mode composite resin chromatography, or a combination thereof.
  • Va 100 liters (or 100-500 liters);
  • the method further comprises after step (e):
  • the virus comprises a lentivirus
  • the method is GMP compliant.
  • step (d) size exclusion chromatography and anion chromatography are carried out sequentially, sequentially or simultaneously.
  • the anionic resin is selected from the group consisting of Capto Q, Capto ImpRes, Capto DEAE.
  • a multimodal composite chromatography resin Capto adhere ImpRes, Capto core 700 is employed.
  • the chromatographic purification treatment is performed by anion chromatography crude purification followed by multi-mode complex chromatography purification.
  • the chromatographic purification treatment is performed by multi-mode conformation chromatography and then subjected to anion chromatography purification.
  • the chromatographic purification treatment is to carry out impurity adsorption removal and virus capture while the two multi-modes are matched in series with the chromatography resin.
  • the chromatographic purification treatment time of the concentrated liquid is 10 L/30 min.
  • the chromatographic purification treatment is carried out at a rate of 20 L of filtrate to be chromated/60 minutes.
  • the weight ratio of the chromatographic medium to the filtrate to be chromatographed is 500 mL: 10 L of filtrate,
  • the sterilizing filter has a pore size of 0.2 ⁇ M.
  • the chromatographic medium is selected from the group consisting of Capto Q ImpRes.
  • the purified recombinant lentiviral vector has one or more characteristics selected from the group consisting of:
  • the filtrate (including the concentrated or unconcentrated filtrate) is subjected to ribozyme treatment prior to performing the chromatographic purification treatment
  • the ribozyme treatment comprises: adding 10 U/ml of ribozyme and incubating at 37 ° C for 30 min.
  • step (b) a microfiltration hollow fiber column is used for microfiltration
  • the microfiltration hollow fiber column is a microfiltration membrane having a cut-off of 0.4-1.0 micrometers (preferably 0.45-0.8 micrometers).
  • the ratio of Vb to Vc is 5 to 50, preferably 10 to 30, more preferably 15 to 25.
  • step (c) concentration is carried out by ultrafiltration.
  • the ultrafiltration uses an ultrafiltration membrane having a cut-off of 100 to 800K.
  • the ultrafiltration hollow fiber column has a cutoff value of 200-1000K, preferably 300-500K.
  • the ultrafiltration is carried out using an ultrafiltration hollow fiber column and an ultrafiltration system.
  • the ultrafiltration system is selected from the group consisting of AKTA flux 6, AKTA readyflux.
  • a purified recombinant lentivirus prepared by the method is provided.
  • a formulation comprising the purified recombinant lentivirus.
  • the formulation is a pharmaceutical composition
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
  • a purification apparatus for the method comprising:
  • (S1) an optional first container for holding a raw material of the recombinant lentivirus to be purified
  • (S2) a microfiltration unit, wherein the microfiltration unit is used for microfiltration treatment of the recombinant lentivirus to be purified, thereby obtaining a microfiltration-treated filtrate;
  • (S5) a collection unit for collecting the purified recombinant lentiviral vector.
  • the first container, the microfiltration unit, the concentration unit, the chromatographic purification unit, and the collection unit are in fluid communication.
  • the chromatographic purification unit comprises: a molecular exclusion chromatography unit and an anion chromatography unit.
  • the molecular exclusion chromatography unit and the anion chromatography unit are each independent;
  • the size exclusion chromatography unit and the anion chromatography unit are integrated.
  • the purification device further comprises:
  • (S6) A ribozyme treatment unit comprising an addition device for adding a ribozyme.
  • the ribozyme processing unit further includes an incubation device for incubating the filtrate to which the ribozyme is added.
  • the inventors have extensively and intensively studied, and through the extensive screening and exploration of purification conditions, for the first time, a rapid, simple and excellent purification method of GMP-scale large-scale purification of recombinant lentivirus has been unexpectedly developed.
  • the purification raw material containing recombinant lentivirus can be purified extremely efficiently, rapidly and on a large scale by using a specific purification medium and specific purification steps and conditions, thereby obtaining high purification, low impurity and no internal content.
  • Recombinant lentiviral preparation of toxin The present invention has been completed on this basis.
  • composite filler resin refers to Capto Q, Capto ImpRes, Capto DEAE.
  • composite filler resin refers to chromatography using a composite filler resin.
  • lentiviral vector As used herein, the terms "recombinant lentivirus", “lentiviral vector” and the like are used interchangeably and refer to a lentiviral vector produced by introducing a particular plasmid into a particular packaging cell. Typically, these lentiviral vectors are useful for subsequent therapeutic or non-therapeutic purposes of transfecting predetermined cells, including cells of humans and non-human mammals.
  • the method set forth in the present invention rapidly obtains a high purity lentiviral formulation by using a GE AKTA device using a combination of, but not limited to, a new generation of Capto Core 700 and Capto adhere ImpRes resin.
  • the recombinant lentiviral vector purified preparation prepared by the method of the invention can be used for the production of cells or gene drugs.
  • High purity lentiviral formulations can be obtained quickly by combining the combination of Capto Core700 and Capto adhere ImpRes for lentiviral purification.
  • AKTA Flux 6 system is cleaned by sterile 1X PBS;
  • AKTA Flux 6 system is cleaned by sterile 1X PBS;
  • microfiltered lentiviral solution is subjected to ultrafiltration through a 300-800K ultrafiltration column and an AKTA Flux 6 system, and the filtrate is discarded;
  • nuclease a concentration of 10 to 1000 U / mL into a 1 ⁇ 2L lentiviral solution and mixing;
  • AKTA Flux 6 system is cleaned by sterile lentiviral cryopreservation
  • the microfiltered lentiviral solution is subjected to ultrafiltration through a 300-800K ultrafiltration column and an AKTA Flux 6 system, and the filtrate is discarded;
  • the lentiviral preparation is stored in an ultra-low temperature freezer ( ⁇ -70 ° C).
  • High-purity lentivirus can be obtained quickly and efficiently by using 0.45-0.8 ⁇ M microfiltration hollow fiber column, 300-800K hollow fiber column and Capto Core700+Capto adhere ImpRes composite packing for stepwise clarification filtration, concentration, exchange and impurity removal. preparation.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Sustainable Development (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

提供了一种GMP级规模化制备重组病毒载体纯化制剂的方法。该方法包括：(a)提供一含待纯化的重组病毒载体的原料料液；(b)将所述料液进行微滤处理，从而获得经微滤处理的滤液，其中所述滤液含有所述重组病毒载体；(c)任选地对所述滤液进行浓缩处理，从而获得经浓缩的滤液；(d)对所述的上一步骤获得的滤液进行层析纯化处理，从而获得含重组病毒载体的粗纯产物；(e)对所述的上一步骤获得的粗纯产物，进行换液和精纯，获得纯化的重组病毒载体。

Description

GMP级规模化制备重组慢病毒载体的纯化制剂的方法 技术领域
本发明涉及生物技术领域，具体地涉及GMP级规模化制备重组慢病毒载体的纯化制剂的方法。
背景技术
基因治疗(gene therapy)是指将外源治疗性基因导入靶细胞，以纠正或补偿因基因缺陷和异常引起的疾病，或通过外源基因表达的产物作用于疾病靶点，以达到治疗目的。
外源基因可通过病毒载体或非病毒载体进行转导或递送，常用的非病毒载体有脂质体、树枝状大分子、非天然阳离子聚合物、天然多糖等。非病毒基因递送载体较为安全、稳定，但其转染效率通常较低。病毒载体是将外源基因包装到天然病毒的外壳中，利用病毒对宿主细胞的感染性将外源基因导入细胞中。常见的病毒载体包括逆转录病毒(recombinant retrovirus，rRV)，重组慢病毒(recombinant lentivirus，rLV)、腺病毒(recombinant adenovirus，rAd)、腺相关病毒(recombinant adeno-associated virus，rAAV)等。病毒载体的转导效率比非病毒载体的转导效率要高很多，特别适合用于侵染难感染的靶细胞，如淋巴细胞。
重组慢病载体是以HIV-1(人类免疫缺陷I型病毒)为基础发展起来的基因治疗载体。区别一般的逆转录病毒载体，它对分裂细胞和非分裂细胞均具有感染能力。重组慢病载体因其体内外生物滴度高和免疫原性低等优势，成为CART细胞和基因治疗的首选转基因载体。
目前的重组慢病毒载体是通过基因改造的方法，使慢病毒基因组中只留下包装信号和目的基因转录原件，而将逆转录酶、包膜蛋白VSVG、以及gag-pol等结构基因分散在2～3个载体上，同时删除致病基因。成熟的慢病毒颗粒通过将多个载体共同转染293T细胞后在细胞内包装而成，并由293T细胞分泌至培养上清，可以通过超速离心或者层析纯化的方法获得。
常规实验室用于获取慢病毒的方式是超速离心，该方法虽然简便但是无法进行工业化放大，且制备的慢病毒的载体可能存在较高的内毒素、BSA、HCP或者核酸等残留，无法直接用于人体。
此外，目前已有的层析纯化方法也存在步骤繁琐、得率低和纯度不够高等缺点，而且难以满足工业化大规模生产和GMP级生产的要求。
因此，本领域迫切需要开发新的、高效的、适合大规模生产且符合GMP级生产要求的制备纯化的慢病毒载体的方法。
发明内容
本发明的目的就是提供一种高效的、适合大规模生产且符合GMP级生产要求的制备纯化的慢病毒载体的方法。
本发明的另一目的是提供用所述方法纯化的重组慢病毒，以及含有所述重组慢病毒的纯化制剂及其应用。
在本发明的第一方面，提供了一种规模化纯化重组病毒载体制剂的方法，所述方法包括以下步骤：
(a)提供一含待纯化的重组病毒载体的原料，所述原料是料液，所述料液的体积为Va；
(b)将所述料液进行微滤处理，从而获得经微滤处理的滤液，其中所述滤液含有所述重组病毒载体，所述滤液的体积为Vb；
(c)任选地对所述滤液进行浓缩处理，从而获得经浓缩的滤液，所述经浓缩的滤液的体积为Vc；
(d)对所述的上一步骤获得的滤液进行层析纯化处理，从而获得含重组病毒载体的粗纯产物；
(e)对所述的上一步骤获得的粗纯产物，进行换液和精纯，获得纯化的重组病毒载体；
其中，所述的层析选自下组：阴离子层析、分子排阻层析、多模式复合树脂层析、或其组合。
在另一优选例中，所述Va≥100升(或为100－500升)；
在另一优选例中，所述方法在步骤(e)之后还包括：
(f)对纯化的重组病毒载体进行换液，置换成含重组病毒载体的病毒冻存液；
(g)对经过溶液置换后的病毒进行过滤除菌，从而获得经除菌的重组病毒载体，
在另一优选例中，所述的病毒包括慢病毒，
在另一优选例中，所述的方法是符合GMP条件。
在另一优选例中，在步骤(d)中，依次、先后或同时进行分子排阻层析和阴离子层析。
在另一优选例中，所述的阴离子树脂选自下组：Capto Q，Capto ImpRes,Capto DEAE。
在另一优选例中，采用多模式复合层析树脂：Capto adhere ImpRes，Capto core 700。
在另一优选例中，所述的层析纯化处理是先进行阴离子层析粗纯，然后进行多模式复合层析精纯。
在另一优选例中，所述的层析纯化处理是先进行多模式符合层析粗纯，然后进行阴离子层析精纯，
在另一优选例中，所述的层析纯化处理是将两种多模式符合层析树脂串联后同时进行杂质吸附去除和病毒捕获，
在另一优选例中，浓缩后料液所述的层析纯化处理的时间为10L/30min，
在另一优选例中，所述的层析纯化处理的处理速度为20L待层析的滤液/60分钟，
在另一优选例中，所述的层析介质与待层析的滤液的重量体积比为500mL：10L滤液，
在另一优选例中，所述的除菌滤器的孔径为0.2μM，
在另一优选例中，所述层析介质选自下组：Capto Q ImpRes。
在另一优选例中，在步骤(d)中，所述的经纯化的重组慢病毒载体具有选自下组的一个或多个特征：
(p1)重组慢病毒载体生物滴度1.06x10 9Tu/mL；
(p2)BSA残留<50ng/mL；
(p3)内毒素<1EU/mL。
在另一优选例中，在进行层析纯化处理之前，对所述滤液(包括经浓缩或未经浓缩的滤液)进行核酶处理，
在另一优选例中，所述的核酶处理包括：加入10U/ml的核酶，在37℃孵育30min，
在另一优选例中，在步骤(b)中，采用微滤中空纤维柱进行微滤，
在另一优选例中，所述的微滤中空纤维柱是截断值(cut-off)为0.4-1.0微米(较佳地0.45-0.8微米)的微滤膜，
在另一优选例中，在步骤(c)中，Vb与Vc之比(Vb/Vc)为5-50，较佳地10-30，更佳地15-25。
在另一优选例中，在步骤(c)中，通过超滤进行浓缩。
在另一优选例中，所述的超滤采用截断值(cut-off)为100～800K的超滤膜，
在另一优选例中，所述超滤中空纤维柱的截断值为200-1000K，较佳地300-500K，
在另一优选例中，所述的超滤采用超滤中空纤维柱和超滤系统进行，
在另一优选例中，所述超滤系统选自下组：AKTA flux 6、AKTA readyflux。
在本发明的第二方面，提供了一种用所述方法制备的纯化的重组慢病毒。
在本发明的第三方面，提供了一种制剂，所述制剂含有所述的纯化的重组慢病毒。
在另一优选例中，所述的制剂为药物组合物，
在另一优选例中，所述的药物组合物还含有药学上可接受的载体。
在本发明的第四方面，提供了一种用于所述方法的纯化装置，包括：
(S1)任选的用于盛放待纯化的重组慢病毒的原料的第一容器；
(S2)微滤单元，所述的微滤单元用于对待纯化的重组慢病毒进行微滤处理，从而获得经微滤处理的滤液；
(S3)任选的浓缩单元，所述的浓缩单元用于对所述滤液进行浓缩处理，从而获得经浓缩的滤液；
(S4)层析纯化单元，所述的层析纯化单元用于对来自微滤单元或来自浓缩单元的滤液进行层析纯化处理，从而获得经纯化的重组慢病毒载体；和
(S5)收集单元，所述收集单元用于收集所述经纯化的重组慢病毒载体。
在另一优选例中，所述的第一容器、微滤单元、浓缩单元、层析纯化单元和收集单元是液体连通的。
在另一优选例中，所述的层析纯化单元包括：分子排阻层析单元和阴离子层析单元。
在另一优选例中，所述的分子排阻层析单元和阴离子层析单元是各自独立的；
在另一优选例中，所述的分子排阻层析单元和阴离子层析单元是合为一体的。
在另一优选例中，所述的纯化装置还包括：
(S6)核酶处理单元，所述核酶处理单元包括用于添加核酶的添加装置。
在另一优选例中，所述的核酶处理单元还包括一孵育装置，用于对添加了核酶的滤液进行孵育处理。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
具体实施方式
本发明人经过广泛而深入的研究，通过对纯化条件的大量筛选和摸索，首次意外地开发了一种快速、简便且纯化效果优异的GMP级大规模纯化重组慢病毒的方法。在本发明方法中，采用特定的纯化介质以及特定的纯化步骤和条件，可以极其高效、快速而大规模地对含重组慢病毒的生产原料进行纯化，从而制得纯化高、杂质少、无内毒素的重组慢病毒制剂。在此基础上完成了本发明。
术语
如本文所用，术语“复合填料树脂”指Capto Q，Capto ImpRes,Capto DEAE。
如本文所用，“复合填料树脂”指采用复合填料树脂进行的层析。
如本文所用，术语“重组慢病毒”、“慢病毒载体”等可互换使用，指通过将特定质粒导入特定的包装细胞后，所产生的慢病毒载体。典型地，这些慢病毒载体可用于后续的治疗目的或非治疗目的的转染预定细胞(包括人和非人哺乳动物的细胞)的反应。
本发明阐述的方法通过使用GE AKTA设备使用新一代Capto Core700和Capto adhere ImpRes树脂组合(但不限于)，快速获得高纯度慢病毒制剂。
采用本发明方法制备的重组慢病毒载体纯化制剂，可用于细胞或基因药品的生产。
本发明的主要优点包括：
通过将Capto Core700和Capto adhere ImpRes组合进行慢病毒纯化可快速获得高纯度慢病毒制剂。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，例如Sambrook等人，分子克隆：实验室手册(New York:Cold Spring Harbor Laboratory Press,1989)中所述的条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数是重量百分比和重量份数。
实施例1.
(1)料液的收获：收集慢病毒料液
(2)微滤澄清：
a)将0.45-0.8μM微滤中空纤维柱与AKTA Flux 6系统进行连接，测试完整性；
b)AKTA Flux 6系统通过1M NaOH进行在线灭菌；
c)AKTA Flux 6系统通过注射用水进行清洗；
d)AKTA Flux 6系统通过无菌1XPBS进行清洗；
e)将20L重组慢病毒料液分两次倒入料液桶，进行微滤，收获滤过液。
(3)超滤浓缩：
a)将300-800K超滤中空纤维柱与AKTA Flux 6系统进行连接，测试完整性；
b)AKTA Flux 6系统通过1M NaOH进行在线灭菌；
c)AKTA Flux 6系统通过注射用水进行清洗；
d)AKTA Flux 6系统通过无菌1XPBS进行清洗；
e)将微滤后的慢病毒料液通过300-800K超滤柱和AKTA Flux 6系统进行超滤浓缩，弃去滤过液；
f)将慢病毒料液由20L浓缩到1～2L。
(4)核酸酶处理：
a)将核酸酶按照10～1000U/mL的比例加入1～2L慢病毒料液中混匀；
b)2～8度过夜孵育。
(5)使用Capto Core700与Capto adhere ImpRes串联进行去除杂质并捕获病毒的操作：
a)将含有500mL的Capto Core700与500mL Capto adhere ImpRes串联后安装到AKTA pure 150层析系统上；
b)AKTA Pure 150系统通过1M NaOH进行在线灭菌；
c)AKTA Pure 150系统通过注射用水进行清洗；
d)AKTA Pure 150系统通过无菌慢病毒冻存液
e)进行平衡；
f)将1～2L料液进行上样，上样结束使用20～50mM Tris-Cl/1～1.5M NaCl进行洗脱，收集洗脱峰。
(6)超滤换液：
a)将300-800K超滤中空纤维柱与AKTA Flux 6系统进行连接，测试完整性；
b)AKTA Flux 6系统通过1M NaOH进行在线灭菌；
c)AKTA Flux 6系统通过注射用水进行清洗；
d)AKTA Flux 6系统通过无菌慢病毒冻存液进行清洗；
e)将微滤后的慢病毒料液通过300-800K超滤柱和AKTA Flux 6系统进行超滤换液，弃去滤过液；
f)收获重组慢病毒载体100～300mL。
(7)过滤除菌与分装冻存：
a)用0.2μM的滤器过滤纯化后的慢病毒料液；
b)终产品按照1mL/管进行分装；
c)慢病毒制剂保存于超低温冰箱(≤-70℃)。
一、结果:
(1)慢病毒终产品浓度2～4×10 9/mL
(2)BSA<50ng/mL；
(3)HCP<1ng/mL；
(4)核酸残留<5pg/mL；
(5)RCL阴性。
二、结论
使用0.45-0.8μM微滤中空纤维柱、300-800K中空纤维柱以及Capto Core700+Capto adhere ImpRes复合填料分步进行澄清过滤、浓缩、换液和杂质的去除，能快速有效地获得高纯度慢病毒制剂。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种规模化纯化重组病毒载体制剂的方法，其特征在于，所述方法包括以下步骤：
    (a)提供一含待纯化的重组病毒载体的原料，所述原料是料液，所述料液的体积为Va；
    (b)将所述料液进行微滤处理，从而获得经微滤处理的滤液，其中所述滤液含有所述重组病毒载体，所述滤液的体积为Vb；
    (c)任选地对所述滤液进行浓缩处理，从而获得经浓缩的滤液，所述经浓缩的滤液的体积为Vc；
    (d)对所述的上一步骤获得的滤液进行层析纯化处理，从而获得含重组病毒载体的粗纯产物；
    (e)对所述的上一步骤获得的粗纯产物，进行换液和精纯，获得纯化的重组病毒载体；
    其中，所述的层析选自下组：阴离子层析、分子排阻层析、多模式复合树脂层析、或其组合。
  2. 如权利要求1所述的方法，其特征在于，所述的阴离子树脂选自下组：Capto Q，Capto ImpRes,Capto DEAE。
  3. 如权利要求1所述的方法，其特征在于，所述的层析纯化处理是先进行阴离子层析粗纯，然后进行多模式复合层析精纯。
  4. 如权利要求1所述的方法，其特征在于，在步骤(d)中，所述的经纯化的重组慢病毒载体具有选自下组的一个或多个特征：
    (p1)重组慢病毒载体生物滴度1.06x10 9Tu/mL；
    (p2)BSA残留<50ng/mL；
    (p3)内毒素<1EU/mL。
  5. 如权利要求1所述的方法，其特征在于，在步骤(c)中，通过超滤进行浓缩。
  6. 一种用权利要求1所述方法制备的纯化的重组慢病毒。
  7. 一种制剂，其特征在于，所述制剂含有权利要求5所述的纯化的重组慢病毒。
  8. 一种用于权利要求1所述方法的纯化装置，其特征在于，包括：
    (S1)任选的用于盛放待纯化的重组慢病毒的原料的第一容器；
    (S2)微滤单元，所述的微滤单元用于对待纯化的重组慢病毒进行微滤处理，从而获得经微滤处理的滤液；
    (S3)任选的浓缩单元，所述的浓缩单元用于对所述滤液进行浓缩处理，从而获得经浓缩的滤液；
    (S4)层析纯化单元，所述的层析纯化单元用于对来自微滤单元或来自浓缩单元的滤液进行层析纯化处理，从而获得经纯化的重组慢病毒载体；和
    (S5)收集单元，所述收集单元用于收集所述经纯化的重组慢病毒载体。
  9. 如权利要求8所述的纯化装置，其特征在于，所述的层析纯化单元包括：分子排阻层析单元和阴离子层析单元。
  10. 如权利要求8所述的纯化装置，其特征在于，所述的纯化装置还包括：
    (S6)核酶处理单元，所述核酶处理单元包括用于添加核酶的添加装置。
PCT/CN2019/080213 2018-03-28 2019-03-28 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 WO2019184995A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020207030556A KR20200136448A (ko) 2018-03-28 2019-03-28 Gmp 등급의 재조합 렌티바이러스 벡터의 정제된 제제의 대규모 제조 방법
SG11202009824WA SG11202009824WA (en) 2018-03-28 2019-03-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at gmp grade
JP2020552824A JP2021518757A (ja) 2018-03-28 2019-03-28 Ｇｍｐグレードでの組換えレンチウイルベクターの精製調製物の大規模調製のための方法
EP19778302.0A EP3778905A4 (en) 2018-03-28 2019-03-28 PROCESS FOR THE LARGE-SCALE PRODUCTION OF CLEANED RECOMBINANT LENTIVIRAL VECTORS IN GMP QUALITY
US17/042,125 US20210009966A1 (en) 2018-03-28 2019-03-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at gmp grade
AU2019241300A AU2019241300A1 (en) 2018-03-28 2019-03-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade
US17/034,168 US20210147826A1 (en) 2018-03-28 2020-09-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at gmp grade
JP2023210248A JP2024041758A (ja) 2018-03-28 2023-12-13 Ｇｍｐグレードでの組換えレンチウイルベクターの精製調製物の大規模調製のための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810264813.X 2018-03-28
CN201810264813.XA CN110317832B (zh) 2018-03-28 2018-03-28 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/034,168 Continuation US20210147826A1 (en) 2018-03-28 2020-09-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at gmp grade

Publications (1)

Publication Number Publication Date
WO2019184995A1 true WO2019184995A1 (zh) 2019-10-03

Family

ID=68058553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/080213 WO2019184995A1 (zh) 2018-03-28 2019-03-28 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法

Country Status (8)

Country Link
US (2) US20210009966A1 (zh)
EP (1) EP3778905A4 (zh)
JP (2) JP2021518757A (zh)
KR (1) KR20200136448A (zh)
CN (1) CN110317832B (zh)
AU (1) AU2019241300A1 (zh)
SG (1) SG11202009824WA (zh)
WO (1) WO2019184995A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CN110714029A (zh) * 2019-11-06 2020-01-21 无锡生基医药科技有限公司 一种慢病毒载体全封闭生产的方法及系统
CN111876393A (zh) * 2020-06-30 2020-11-03 恒瑞源正（上海）生物科技有限公司 一种大规模快速生产高纯度高活性慢病毒载体的方法
CN111876392A (zh) * 2020-06-30 2020-11-03 恒瑞源正（上海）生物科技有限公司 一种大规模快速生产病毒载体的方法
CN116590346B (zh) * 2020-09-15 2024-05-14 上海药明巨诺生物医药研发有限公司 一种慢病毒载体纯化方法
CN113373120B (zh) * 2021-06-18 2022-04-26 浙江康佰裕生物科技有限公司 Gmp级逆转录病毒载体的纯化方法与应用
CN116769736B (zh) * 2023-08-17 2023-11-14 赛奥斯博生物科技(北京)有限公司 一种快速纯化慢病毒的生产工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039459A2 (en) * 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175688A1 (en) * 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
EP1718738A2 (en) * 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
US20080026448A1 (en) * 2006-02-15 2008-01-31 Lydersen Bjorn K Production of HIV
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
KR20110004354A (ko) * 2007-12-21 2011-01-13 와이어쓰 엘엘씨 유전자 변형된 약독화 수포성 구내염 바이러스, 이의 조성물 및 사용 방법
DK2350268T3 (en) * 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
CN101993472A (zh) * 2009-08-19 2011-03-30 中国科学院上海生命科学研究院 一种微型多用途生物大分子分离纯化装置
CN202226858U (zh) * 2011-09-21 2012-05-23 扬州优邦生物制药有限公司 一种病毒液纯化、浓缩装置
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN103642760B (zh) * 2013-11-14 2016-08-17 北京万泰生物药业股份有限公司 一种制备柯萨奇a16型病毒完整实心颗粒的方法
FR3014901B1 (fr) * 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3256565A1 (en) * 2015-02-09 2017-12-20 Univercells NV System, apparatus and method for the production of cells and/or cell products
CN105420202A (zh) * 2015-12-30 2016-03-23 苏州药明康德检测检验有限责任公司 病毒纯化放大方法
CN106474466B (zh) * 2016-12-07 2018-04-13 申联生物医药（上海）股份有限公司 一种口蹄疫疫苗的制备方法
CN206635330U (zh) * 2017-03-23 2017-11-14 上海海利生物技术股份有限公司 一种病毒颗粒抗原纯化浓缩设备
CN107384877B (zh) * 2017-08-18 2020-09-08 深圳源兴基因技术有限公司 一种慢病毒的纯化方法
CN107630037A (zh) * 2017-10-19 2018-01-26 和元生物技术（上海）股份有限公司 一种获得高纯度腺相关病毒载体的纯化工艺

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039459A2 (en) * 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAI, . JINGJING ET AL.: "Lentiviral Vector Packaging and Production Method", JOURNAL OF YANGTZE UNIVERSITY ( NAT SCI EDIT ), vol. 11, no. 9, 25 March 2014 (2014-03-25), XP009523640, ISSN: 1673-1409 *
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
See also references of EP3778905A4
VANESSA BANDEIRA, CRISTINA PEIXOTO, ANA F. RODRIGUES PEDRO E. CRUZ, PAULA M. ALVES, ANA S. COROADINHA, MANUEL J. T. CARRONDO: "Downstream Processing of Lentiviral Vectors: Releasing Bottlenecks", HUMAN GENE THERAPY METHODS, vol. 23, no. 4, 31 August 2012 (2012-08-31), pages 255 - 263, XP055639687, ISSN: 1946-6536, DOI: 10.1089/hgtb.2012.059 *

Also Published As

Publication number Publication date
CN110317832A (zh) 2019-10-11
CN110317832B (zh) 2022-07-05
JP2024041758A (ja) 2024-03-27
JP2021518757A (ja) 2021-08-05
US20210147826A1 (en) 2021-05-20
EP3778905A1 (en) 2021-02-17
EP3778905A4 (en) 2021-12-22
KR20200136448A (ko) 2020-12-07
SG11202009824WA (en) 2020-11-27
US20210009966A1 (en) 2021-01-14
AU2019241300A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
WO2019184995A1 (zh) Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
Bandeira et al. Downstream processing of lentiviral vectors: releasing bottlenecks
Kuiper et al. Purification of a functional gene therapy vector derived from Moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography
Rodrigues et al. Purification of retroviral vectors for clinical application: biological implications and technological challenges
AU2017391164B2 (en) Adeno-associated virus purification methods
JP2000500028A (ja) 核酸の精製方法
JP2014521330A (ja) 真核細胞の形質導入に有用なウイルスベースのベクター組成物
WO2019184996A1 (zh) Gmp级无血清悬浮细胞大规模生产慢病毒的方法
US9352052B2 (en) Retrograde transport viral vector system having envelope comprising fused glycoprotein
US20200149065A1 (en) Foamy viral vector compositions and methods for the manufacture of same
Rosales Gerpe et al. Optimized pre-clinical grade production of two novel lentiviral vector pseudotypes for lung gene delivery
Boroujeni et al. The superiority of sucrose cushion centrifugation to ultrafiltration and PEGylation in generating high-titer lentivirus particles and transducing stem cells with enhanced efficiency
CN103842501B (zh) 病毒载体纯化系统
WO2022250035A1 (ja) 細胞外小胞の分離精製方法
CN113373120B (zh) Gmp级逆转录病毒载体的纯化方法与应用
Gashti et al. Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate
JPWO2019184995A5 (zh)
US11807865B2 (en) Large commercial scale lentiviral vector production system and vectors produced thereby
JP2024075766A (ja) Ｇｍｐレベルの無血清懸濁液細胞を用いるレンチウイルスの大規模製造方法
WO2023177639A1 (en) Lentiviral manufacturing platform
EP4196596A1 (en) Methods for producing clinical-grade lentiviral vector
US20210301307A1 (en) Ldlr negative packaging cell line for the production of vsv-g pseudotyped retroviral vector particles or virus particles thereof
CN117660373A (zh) 一种慢病毒大规模纯化方法及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19778302

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020552824

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019241300

Country of ref document: AU

Date of ref document: 20190328

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20207030556

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019778302

Country of ref document: EP

Effective date: 20201028